Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BJ-005 |
Synonyms | |
Therapy Description |
BJ-005 is a fusion protein comprising an anti-PD-L1 (CD274) antibody linked to the extracellular domain of Tgfbr2, which may decrease TGFbeta- and PD-L1-mediated immunosuppression, leading to increased antitumor immune response and reduced tumor cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BJ-005 | BJ 005|BJ005 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | BJ-005 is a fusion protein comprising an anti-PD-L1 (CD274) antibody linked to the extracellular domain of Tgfbr2, which may decrease TGFbeta- and PD-L1-mediated immunosuppression, leading to increased antitumor immune response and reduced tumor cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05115292 | Phase I | BJ-005 | A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma | Active, not recruiting | USA | 0 |